MTEM | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 24%

Liquidity 31%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-23.43%

1 Month

-71.03%

3 Months

-92.15%

6 Months

-90.07%

1 Year

-97.13%

2 Year

-97.94%

Key data

Stock price

$0.11

P/E Ratio

-0.64

DAY RANGE

$0.15 - $0.59

EPS

$0.77

52 WEEK RANGE

$0.15 - $4.12

52 WEEK CHANGE

-$97.16

MARKET CAP

10.073 M

YIELD

N/A

SHARES OUTSTANDING

6.584 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,997,562

AVERAGE 30 VOLUME

$14,897,088

Company detail

CEO: Eric E. Poma
Region: US
Website: www.thresholdpharm.com
Employees: 260
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Molecular Templates, Inc. develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45.

MTEM - Molecular Templates, Inc.